RBC Capital Maintains Outperform on Legend Biotech, Raises Price Target to $64

Benzinga Newsdesk www.benzinga.com Positive 92.2%

Neg 0% Neu 0% Pos 92.2%

RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and raises the price target from $62 to $64.